Innovations in Diabetes Care for a Better “New Normal” Beyond COVID-19

Authors

Shivani Agarwal, Fleischer Institute for Diabetes and Metabolism, NY-Regional Center for Diabetes Translational Research, Albert Einstein College of Medicine, Bronx, New York 10461
Michelle L. Griffith, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232
Elizabeth J. Murphy, Division of Endocrinology, Zuckerberg San Francisco General: University of California, San Francisco, California 94110
Carol Greenlee, Western Slope Endocrinology, Grand Junction, Colorado 81501
Jeffrey Boord, Parkview Health System, Fort Wayne, Indiana 46805
Robert A. Gabbay, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215

Document Type

Article

Publication Date

2021

Abstract

The coronavirus disease pandemic has created opportunities for innovation in diabetes care that were not possible before. From the lens of this “new normal” state, we have an opportunity to rapidly implement, test, and iterate models of diabetes care to achieve the quadruple aim of improving medical outcomes, patient experience, provider satisfaction, and reducing costs. In this perspective, we discuss several innovative diabetes models of care which promote collaborative care models and improve access to high-quality specialty diabetes care. We discuss ongoing threats to diabetes care innovation, and offer practical solutions to foster evolution and sustain current strides made during the pandemic.

Recommended Citation

Shivani Agarwal, Michelle L Griffith, Elizabeth J Murphy, Carol Greenlee, Jeffrey Boord, Robert A Gabbay, for the Innovative Models of Diabetes Care Taskforce of the Endocrine Society, Innovations in Diabetes Care for a Better “New Normal” Beyond COVID-19, The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 1, January 2021, Pages e377–e381, https://doi.org/10.1210/clinem/dgaa704